Speaker
Description
Background: Migration patterns are diversifying globally, and in 2024 over 5 million migrants arrived in the European Union (EU). Newly arrived migrants (defined here as individuals relocating into countries in the EU between 2020-2024) are identified by European Centre for Disease Prevention and Control (ECDC) as a priority population for entry health assessments. These assessments represent a key opportunity to prevent infection-related cancers. But currently, ECDC guidance only includes prevention services for one of the main cancer-causing infections -- viral hepatatitis (and only for migrants from a small number of countries) -- and excludes the two largest infectious causes: HPV (cervical cancer) and H. pylori (gastric cancer).
Methods: Using a publicly available competing risk model (ATLAS, from IARC/WHO) and data on migrant population, cancer incidence, and preventive interventions, we estimated the lifetime expected burden of hepatocellular carcinoma (HCC), cervical cancer (CvC), and gastric cancer (GC) cases among migrants arriving in the EU over the most recent five years, and the proportion that could be preventable through vaccination and screening upon arrival.
Results: Among newly arrived migrants, we expect 635,000 cancer cases over their lifetime (144,000 HCC, 154,000 CvC, 336,000 GC). Current ECDC-recommended hepatitis screening could prevent 15% of HCC cases among migrants, while adding CvC and GC prevention could prevent 55% and 44% of cases, respectively. Expanding viral hepatitis prevention services to a broader criteria of eligibility based on ASIR could increase the number of HCC cases prevented by 83%.
Conclusions: Migrants to the EU may bear a large burden of preventable cancer cases without access to simple, appropriate prevention services. Providing these health services at entry could help overcome healthcare access barriers. Expanding eligibility and ensuring care continuity throughout migrants' stay in the host country could further increase impact.